ddx3

DDX3-IN-2 is an ATP-dependent RNA deconjugase (DDX3) inhibitor with broad-spectrum antiviral activity and is used in the study of HIV infection and dengue virus infection.

DDX3-IN-1 (Compound 16f) is a DDX3 (DEAD box polypeptide 3) inhibitor (IC50 >100 μM) with antiviral activity against HIV and HCV, with EC50 values of >50 and >36 μM, respectively.

RK33 (RK 33) is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.

GBM CSCs-IN-1 (Compound (−)-20), a rocaglate derivative, potently inhibits glioblastoma stem cells (GBM CSCs) and exhibits an EC50 of 45 nM by targeting the RNA helicase DDX3. Additionally, it induces apoptosis in these cells.

Ketorolac (RS37619) hydrochloride is a nonsteroidal anti-inflammatory drug and a non-selective COX inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in a 0.5% ophthalmic solution format for the investigation of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and post-operative ocular inflammation pain. Additionally, Ketorolac hydrochloride serves as a DDX3 inhibitor, making it pertinent for research in cancer therapies.

Avenanthramide A is a naturally occurring, orally active plant defensin that binds to and inhibits RNA helicase DDX3, induces mitochondrial swelling and CRC cell apoptosis, increases ROS production, exhibits antitumor activity, and can be used in colorectal cancer research.

Ketorolac (RS37619) hemicalcium is a nonselective COX inhibitor with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This non-steroidal anti-inflammatory drug (NSAID) is used as a 0.5% ophthalmic solution for researching allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, it is a DDX3 inhibitor applicable in cancer research [1] [4].